Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Bristol-Myers Squibb Co's Revenue for the
three
months ended in Mar. 2026 was $11,489 Mil. Bristol-Myers Squibb Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was $8,770 Mil.
Hence, Bristol-Myers Squibb Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.31.
Bristol-Myers Squibb Co (LIM:BMY) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Bristol-Myers Squibb Co Receivables Turnover Related Terms
Bristol-Myers Squibb Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Bristol-Myers Squibb Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co Receivables Turnover Chart
LIM:BMY vs PFE, GILD, AMGN: Receivables Turnover Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co (LIM:BMY) has a Receivables Turnover of 1.31 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bristol-Myers Squibb Co and its competitors. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #443 out of 948 companies in the Drug Manufacturers industry, placing it in the top 46.7%.
Is Bristol-Myers Squibb Co's Receivables Turnover too high?
Bristol-Myers Squibb Co's current Receivables Turnover is 1.31. The Drug Manufacturers industry median Receivables Turnover is 5.07. Bristol-Myers Squibb Co's value of 1.31 is 74.2% below this industry median. Based on the distribution chart, Bristol-Myers Squibb Co ranks #443 out of 948 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bristol-Myers Squibb Co has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Receivables Turnover compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #443 out of 948 companies for Receivables Turnover. This puts Bristol-Myers Squibb Co in the upper half of its industry. The industry median Receivables Turnover is 5.07. Bristol-Myers Squibb Co's value of 1.31 is 74.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bristol-Myers Squibb Co's current Receivables Turnover of 1.31 is 74.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bristol-Myers Squibb Co and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current Receivables Turnover is 1.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (LIM:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is $48.21, compared to a current price of $56.98 — trading 18.2% above its estimated fair value. The current Receivables Turnover is 1.31 and 74.2% below the Drug Manufacturers industry median of 5.07. Bristol-Myers Squibb Co's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Bristol-Myers Squibb Co (LIM:BMY), the current Receivables Turnover is 1.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (LIM:BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of $56.98 is trading 18.2% above its estimated GF Value™ of $48.21.
GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.
Key valuation signals for LIM:BMY:
Receivables Turnover: 1.31
GF Value™: $48.21 vs. price of $56.98 (18.2% above fair value)
Industry Position: 74.2% below the Drug Manufacturers median (#443 of 948)
No single metric tells the full story. See the LIM:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
56GF Score
Get the complete analysis for LIM:BMY
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIM:BMY has been successfully added to your 
